Independent effect of alanine transaminase on the incidence of type 2 diabetes mellitus, stratified by age and gender: A secondary analysis based on a large cohort study in China

Prevalence of type 2 diabetes mellitus (DM) tends to increasing worldwide. The main cause of death in type 2 DM is coronaryheart disease (CHD) and its mortality rate can increase 2 to 4 times compared to non-diabetics. One of the risk factors in CHD isdyslipidemia. To know the lipid profile based on age and gender and to assess the relation of total cholesterol, LDL, HDL, and TG levelto age. Descriptive retrospective study in patients with type 2 DM who are 45 years old and over. From 100 Type 2 DM patients, in theDepartment of Internal Medicine, Dr. Wahidin Sudirohusodo Hospital, Makassar, period of June to December 2005, the largest age groupwith dyslipidemia was > 59 years old, with increase LDL level, 32.73% in males and 46.67% in females. There was a significant relationbetween the in crease of TG (p = 0.03) and the decrease of HDL (p = 0.02) with age. Dyslipidemia in type 2 DM patients at age group> 59 years old was shown by an increase in LDL level. The increase of TG and decrease of HDL level were significant in all age groups.Restriction of this study was not to check the antilipidemic medicine used. Early dyslipidemia of Type 2 DM should be known by lipidfraction determination and further dyslipidemia study should be conducted to predict the risk of CHD.

Download Full-text

Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up

European Psychiatry ◽

10.1016/j.eurpsy.2011.02.009 ◽

2012 ◽

Vol 27 (1) ◽

pp. 33-42 ◽

Cited By ~ 47

Author(s):

D. Schoepf ◽

R. Potluri ◽

H. Uppal ◽

A. Natalwala ◽

P. Narendran ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Excess Mortality ◽

Age And Gender ◽

Predictors Of Mortality ◽

Co Morbidity ◽

And Gender ◽

The Impact

AbstractObjectivePhysical co-morbidity including type 2 diabetes mellitus is more prevalent in patients with schizophrenia compared to the general population. However, there is little consistent evidence that co-morbidity with diabetes mellitus and/or other diseases leads to excess mortality in schizophrenia. Thus, we investigated whether co-morbidity with diabetes and other somatic diseases is increased in schizophrenics, and if these are equally or more relevant predictors of mortality in schizophrenia than in age- and gender-matched hospitalised controls.MethodsDuring 2000–2007, 679 patients with schizophrenia were admitted to University Hospital Birmingham NHS Trust. Co-morbidities were compared with 88,778 age- and gender group-matched hospital controls. Predictors of mortality were identified using forward Cox regression models.ResultsThe prevalence of type 2 diabetes mellitus was increased in schizophrenia compared to hospitalised controls (11.3% versus 6.3%). The initial prevalence of type 2 diabetes mellitus was significantly higher in the 100 later deceased schizophrenic patients (24.0%) than in those 579 surviving over 7 years (9.2%). Predictors of mortality in schizophrenia were found to be age (relative risk [RR] = 1.1/year), type 2 diabetes mellitus (RR = 2.2), pneumonia (RR = 2.7), heart failure (RR = 2.9) and chronic renal failure (RR = 3.2). The impact of diabetes mellitus on mortality was significantly higher in schizophrenia than in hospital controls (RR = 2.2 versus RR = 1.1). In agreement, deceased schizophrenics had significantly suffered more diabetes mellitus than deceased controls (24.0 versus 10.5%). The relative risks of mortality for other disorders and their prevalence in later deceased subjects did not significantly differ between schizophrenia and controls.ConclusionSchizophrenics have more and additionally suffer more from diabetes: co-morbidity with diabetes mellitus is increased in schizophrenia in comparison with hospital controls; type 2 diabetes mellitus causes significant excess mortality in schizophrenia. Thus, monitoring for and prevention of type 2 diabetes mellitus is of utmost relevance in hospitalised patients with schizophrenia.

Download Full-text

Impact on Diabetes Mellitus on the Epicardial Coronary Flow Velocity Assessed by the Thrombolysis in Myocardial Infarction Frame Count

Angiology ◽

10.1177/0003319708321187 ◽

2008 ◽

Vol 60 (4) ◽

pp. 431-440 ◽

Cited By ~ 1

Author(s):

Ahmet Soylu ◽

Kurtulus Ozdemir ◽

Mehmet Akif Duzenli ◽

Mehmet Yazici ◽

Mehmet Tokac

Keyword(s):

Diabetes Mellitus ◽

Myocardial Infarction ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Flow Velocity ◽

Coronary Arteries ◽

Coronary Flow ◽

Coronary Flow Velocity ◽

And Gender

The aim of this study is to evaluate the effect of type 2 diabetes mellitus on epicardial coronary flow velocity assessed by the thrombolysis in myocardial infarction frame count. The thrombolysis in myocardial infarction frame count was measured in 272 coronary arteries from 101 patients with type 2 diabetes mellitus and in 271 coronary arteries from 104 age- and gender-matched patients without type 2 diabetes mellitus referred for coronary angiography. The thrombolysis in myocardial infarction frame count was measured only in normal arteries or in arteries without significant lesion. By both univariate and multivariate analysis, the thrombolysis in myocardial infarction frame count was not related with either type 2 diabetes mellitus or the duration and glycated hemoglobin levels in the patients with type 2 diabetes mellitus. The thrombolysis in myocardial infarction frame count was significantly associated with body surface area, heart rate, and proximal coronary artery diameter. Type 2 diabetes mellitus did not affect epicardial coronary flow velocity assessed by the thrombolysis in myocardial infarction frame count.

Download Full-text

The Association Between Gender and Complications of Type 2 Diabetes Mellitus Among Patients in Almarj City-Libya

AL-MUKHTAR JOURNAL OF SCIENCES ◽

10.54172/mjsc.v35i2.306 ◽

2020 ◽

Vol 35 (2) ◽

pp. 130-138

Author(s):

Fatma KH. Ali Ehmaida ◽

Sokaina Saad Hemdan ◽

Asmaa M. Aljebaly

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Respiratory Dysfunction ◽

Type 2 Diabetic Mellitus ◽

Foot Complications ◽

Life Threatening ◽

And Gender ◽

The Relationship

This study was carried out to provide new data on patients with type 2 diabetes mellitus and any suggestions for the prevention of what is a life-threatening disorder. Four hundred and seventy-three type 2 diabetic mellitus patients from Almarj general hospital were used: (222) females and (251) males for the period from October -2017 to April – 2018.The study focused on the relationship between genders and complications of diabetes mellitus. The study showed no significant differences (P > 0.05) between hypertension, heart disease, respiratory dysfunction, nephropathy, urinary tract infection, anemia, hypothyroidism, diabetic ketoacidosis, gastric infection, and gender. On the other hand, a significant (P ≤ 0.05) relationship was found between hepatopathy and foot complications and gender. Findings showed that males with the risk of the dangers of type 2 diabetes mellitus complications were more than females in Almarj city.

Download Full-text

Dapagliflozin does not affect short-term blood pressure variability in patients with type-2 diabetes mellitus

American Journal of Hypertension ◽

10.1093/ajh/hpaa207 ◽

2020 ◽

Author(s):

Eirini Papadopoulou ◽

Marieta P Theodorakopoulou ◽

Charalampos Loutradis ◽

Georgios Tzanis ◽

Glykeria Tzatzagou ◽

...

Keyword(s):

Diabetes Mellitus ◽

Blood Pressure ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Blood Pressure Variability ◽

Controlled Trial ◽

Secondary Analysis ◽

Short Term ◽

Double Blind

Abstract Background Increased blood-pressure-variability (BPV) is associated with increased cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus (T2DM). Sodium-glucose-co-transporter-2 (SGLT-2) inhibitors decrease the incidence of cardiovascular events, renal events, and death in this population. This study aimed to evaluate the effect of dapagliflozin on short-term BPV in patients with T2DM. Methods This is a secondary analysis of a double-blind, randomized, placebo-controlled trial in 85 patients with T2DM (NCT02887677). Subjects were randomized to oral dapagliflozin 10mg once daily or placebo for 12 weeks. All participants underwent 24-h ambulatory blood pressure (BP) monitoring with the Mobil-O-Graph NG device at baseline and study-end. Standard-deviation (SD), weighted-SD (wSD), coefficient-of-variation (CV), average-real-variability (ARV) and variation-independent-of-mean (VIM) were calculated with validated formulae for the 24-h and the daytime and nighttime periods. Results Dapagliflozin reduced 24-h brachial BP compared to placebo. From baseline to study-end 24-h brachial BPV indexes did not change with dapagliflozin (SBP-ARV: 11.51±3.45 vs 11.05±3.35; p=0.326, SBP-wSD: 13.59±3.60 vs 13.48±3.33; p=0.811) or placebo (SBP-ARV: 11.47±3.63 vs 11.05±3.00; p=0.388, SBP-wSD: 13.85±4.38 vs 13.97±3.87 ; p=0.308). Similarly, no significant changes in BPV indexes for daytime and nighttime were observed in any group. At study-end, no differences between the groups were observed for any BPV index. Deltas(Δ) of all indexes during follow-up were minimal and not different between-groups (SBP-wSD: dapagliflozin: -0.11±3.05 vs placebo: 0.12±4.20; p=0.227). Conclusions This study is the first to evaluate the effects of an SGLT-2 inhibitor on short-term BPV in patients with T2DM, showing no effect on dapagliflozin on all BPV indexes studied.

Download Full-text

Non-linear relationship between gamma-glutamyl transferase and type 2 diabetes mellitus risk: secondary analysis of a prospective cohort study

Journal of International Medical Research ◽

10.1177/0300060520937911 ◽

2020 ◽

Vol 48 (7) ◽

pp. 030006052093791

Author(s):

Hao Wang ◽

Lixia Li ◽

Shouyan Zhang

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Linear Relationship ◽

Secondary Analysis ◽

Gamma Glutamyl Transferase ◽

Non Linear ◽

Glutamyl Transferase ◽

Study Participants

Objective To investigate the association between gamma-glutamyl transferase (GGT) and type 2 diabetes mellitus (T2DM) risk. Methods This was a secondary analysis based on a publicly available DRYAD dataset that included 15 444 study participants that received medical examinations at a single centre in Japan between 2004 and 2015. Crude, minimally-adjusted and fully-adjusted regression models were used to evaluate the relationship between GGT levels and T2DM risk. Results The study participants (mean ± SD age of 43.72 ± 8.90 years; 8415 of 15 444 [54.49%] were male) were followed-up for a median of 1968 days (5.39 years). After adjusting for potential covariates, a non-linear relationship between the baseline GGT level and T2DM incidence was observed. The inflection point for T2DM risk was 10 IU/l GGT; below this point, the T2DM incidence increased by 1.18-fold per unit change in GGT. Above this point, the association between GGT and the incidence rate of T2DM became nonsignificant. Conclusion Baseline GGT exhibited a non-linear association with T2DM incidence. Elevated GGT levels should be incorporated into routine screening for individuals at high risk of T2DM, allowing for early intervention targeting GGT to potentially reduce T2DM-related morbidity.

Download Full-text